Under the leadership of Dr. Clay Siegall at the Seattle Genetics, the group has grown from a mere start-up to a leader in cancer research and treatment. In a recent interview with Inspire, he shares the plans, drug portfolio as well as its position in the 21st-century drug industry.
The Inspiration for Starting the Business
The interest was sparked at the University of Maryland while studying Zoology. It was even compounded the more by the power of technology and his zeal to overcome disease with reason. He quickly learned to the several cancer treatment options like chemotherapy, Seattle Genetics Makes Moneysurgery, and amputation, and that is where he started it all.
How Seattle Genetics Makes Money
The first is from selling their own proprietary drugs, the FDA approved antibodies. They also sell ADCetris. They are also earning from their partnerships for licensing and technological applications, this being despite the fact that 1 out of 10 candidate drugs gets approved by FDA. They started making profits exactly 10 years after getting their IPO.
Seattle Genetics uses referrals to increase their customer base. They also spend time negotiating deals, wining and dining with potential clients. They also have an expert legal team that handles all their technical patenting issues.
The Career of Dr. Siegall at Seattle Genetics
Dr. Clay Siegall was a leading co-founder of the Seattle Genetics in 1998. He serves as its President, Chairman of the Board of Directors and the CEO. The company has built a rich network of antibody-related treatments and cancer therapies. One of their successes in the field is the application of ADCETRIS which was approved by FDA in 2011.
Dr.Siegall has been able to secure more than $750 million through private and public financial sourcing and partnerships. He worked for the Bristol-Myers Squibb Research Institute, 1991-1997. Other international firms that have benefited from this industry include:
- The National Cancer Institute(1988-1991)
- Member of the Board of Directors for the Alder Biopharmaceuticals.
Academics and Professionalism
Dr. Clay Siegall has authored more than 70 publications in cancer treatment and medicine. He owns more than 15 patents. He attended the University of Maryland for his undergraduate studies and proceeded to George Washington University for his Ph.D. in Genetics.